- What is the current status of Coronis Neurosciences?
- Coronis Neurosciences is currently inactive, having ceased operations in May 2022.
- When was Coronis Neurosciences founded?
- Coronis Neurosciences was founded in January 2014.
- What is Coronis Neurosciences' primary focus?
- Coronis Neurosciences is a specialty pharmaceutical company focused on developing therapies for neurocognitive and neurodegenerative disorders.
- What is Coronis Neurosciences' lead drug candidate?
- Coronis Neurosciences' lead drug candidate is CP201, developed to treat ADNP syndrome, a rare neurogenetic disease.
- What other drug is Coronis Neurosciences developing?
- Coronis Neurosciences is also developing CP101, a drug aimed at treating cognitive impairment associated with schizophrenia (CIAS).
- How many employees does Coronis Neurosciences have?
- Coronis Neurosciences has 1-10 employees.
- When was Coronis Neurosciences' last known funding round?
- Coronis Neurosciences had a funding round in January 2017, with ADNP-KRF as an investor.
- Who are the key executives at Coronis Neurosciences?
- Eric J. Messika is the President & CEO, and Illana Gozes is the CSO of Coronis Neurosciences.